Applied Therapeutics Supports 15th Annual Rare Disease Day
28 Febbraio 2022 - 1:30PM
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need, today is recognizing the 15th Annual
Rare Disease Day to help elevate awareness of rare diseases and
call attention to the unique challenges facing people with rare
diseases.
Applied Therapeutics is proud to support Rare
Disease Day events across the U.S., including participating in the
5th Annual GLOW for Galactosemia Event in Knoxville,
Tennessee, and virtually supporting GLOW teams across the country
as they raise awareness of Galactosemia, a rare genetic metabolic
disease resulting in an inability to metabolize the sugar
galactose, which is found in foods and is also synthesized by the
body. The company is collaborating with advocacy partners on a wide
range of Galactosemia initiatives throughout the year, including
Race 4 Jase and Fore Joey’s Cause. Applied Therapeutics is also
partnering with the Charcot-Marie-Tooth Foundation and the
Hereditary Neuropathy Foundation to raise awareness of SORD
Deficiency, a rare disease which results in a progressive,
debilitating hereditary neuropathy.
“We are pleased to support advocacy events such
as GLOW for Galactosemia, and appreciate the tireless efforts of
our advocacy partners, who raise awareness about the impact of rare
diseases,” said Shoshana Shendelman, PhD, Founder and CEO of
Applied Therapeutics. “We are committed to developing treatments
for rare diseases with high unmet medical need, such as
Galactosemia, SORD Deficiency and PMM2-CDG.”
About Rare Disease
Day
Rare Disease Day takes
place every year on the last day of February to raise awareness
among the public and decision-makers about rare diseases and their
impact on patients’ lives. It was established in 2008 by EURORDIS,
the organization representing rare disease patients in Europe, and
is now observed in more than 80 nations. In the U.S., Rare Disease
Day is sponsored by the National Organization for Rare Disorders
(NORD), the largest and leading independent, non-profit
organization committed to the identification, treatment, and cure
of rare diseases. For more information about Rare Disease Day in
the U.S. and to search for information about rare diseases, visit
NORD’s website, rarediseases.org/rare-disease-day.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates against validated molecular targets in indications of
high unmet medical need. Applied Therapeutics’ portfolio includes
three Phase 3 programs for diseases with high unmet medical need
and no approved treatment options. The Company’s lead drug
candidate, AT-007, is a novel central nervous system penetrant
Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare
metabolic diseases, including Galactosemia and SORD Deficiency. The
Company is also developing AT-001, a novel potent ARI, for the
treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of
the heart.
To learn more, please visit
www.appliedtherapeutics.com and follow the company on Twitter
@Applied_Tx. A copy of the Company’s February 2022 Corporate
Presentation is posted to the Investor Relations section of Applied
Therapeutics’ website.
Contacts
Investors:Maeve Conneighton, Eric Kasper (212)
600-1902 orappliedtherapeutics@argotpartners.com
Media:media@appliedtherapeutics.com
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Applied Therapeutics (NASDAQ:APLT)
Storico
Da Set 2023 a Set 2024